Logo

Arbor Biotechnologies: Mark Angelino

Mar 03, 2021

Arbor Biotechnologies has appointed Mark Angelino to its board of directors. Angelino has more than 20 years of expertise in working with numerous pharmaceutical companies, Arbor said. He was the cofounder and chief operating officer of Generation Bio from 2016 until 2021, and has also served as as senior vice president of pharmaceutical sciences and the rare disease franchise head at Bluebird Bio from 2012 until 2016. He also served as senior director of R&D and site head in Cambridge, Massachusetts for Baxter Healthcare from 2010 to 2012. 

Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.